RxDoctor Payments Data

Andrea Thompson, NP

Nurse Practitioner · Bunnell, FLNPI 1346717881

Payments from drug & device makers

$3,144in general payments, 2019–2025

Across 157 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$541
  • AbbVie$458
  • AstraZeneca$352
  • Lilly USA, LLC$332
  • Exact Sciences$291
  • Idorsia Pharmaceuticals US Inc$216
  • plus $954 from 13 others

What the payments were for

  • Food & beverage$3,135100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,144 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$1,272
Medicare patients
12
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$98,668
MounjaroTirzepatide53$67,790
FarxigaDapagliflozin Propanediol24$34,669
JardianceEmpagliflozin22$32,974
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,799
LinzessLinaclotide16$14,315
EliquisApixaban19$12,970
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,097
Levothyroxine Sodium187$2,573
Albuterol Sulfate HfaAlbuterol Sulfate81$2,550
Estradiol49$1,908
Rosuvastatin Calcium129$1,631
Duloxetine Hcl62$1,411
SynthroidLevothyroxine Sodium11$1,411
Losartan Potassium124$1,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$541$98,66852 claims
Lilly USA, LLCMounjaro$332$67,79053 claims
AstraZenecaFarxiga, Breztri Aerosphere$352$42,76635 claims
Boehringer IngelheimJardiance$17$32,97422 claims
GSKTrelegy Ellipta$145$17,79915 claims
AbbVieLinzess, Synthroid$458$15,72627 claims
PfizerEliquis$20$12,97019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Bunnell

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →